New Reclast post-fracture study results released

Published as an early-release article in NEJM, results from the landmark osteoporosis Recurrent Fracture Trial of once-yearly treatment with zoledronic acid (Reclast, Novartis) were also simultaneously presented at the annual meeting of the American Society for Bone and Mineral Research. In patients who had experienced a previous hip fracture, a 35% reduction in the risk of all new clinical fractures was observed as well as a 28% reduction in risk of overall mortality when compared with placebo. The study, which included more than 2,100 men and women, found that Reclast reduced the risk of new spine fractures by 46% and new non-spine fractures by 27%. According to Novartis, data from this trial will be submitted to regulatory authorities worldwide by the end of this year in an effort to broaden the indication for the drug. Reclast is currently indicated for treatment of postmenopausal osteoporosis.

Click here to see more articles from Drug Topics Daily News.

To go to the Drug Topics homepage, click here.